SOPH
SOPHiA GENETICS S.A.
NASDAQ · Healthcare · Medical - Healthcare Information Services · CH
$8.16
−1.69%Aug 4, 2026, 10:45 UTC
SOPHiA GENETICS reported financial results for the second quarter ended June 30, 2026, with revenue of $23.3 million, up 27% year-over-year, and a net loss of $22.4 million.
Aug 4, 2026, 10:15 UTC
SOPHiA GENETICS announced a global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies.
Source:Jun 22, 2026, 12:25 UTC
SOPHiA GENETICS shareholders elected Dr. Jurgi Camblong as Executive Chairman and Ross Muken as a new board member at the 2026 Annual General Meeting.
Jun 19, 2026, 12:00 UTC
SOPHiA GENETICS closed a $57.5 million public offering of ordinary shares, including full exercise of underwriters' option for additional shares.
Source:Jun 16, 2026, 20:20 UTC
SOPHiA GENETICS announced a proposed underwritten public offering of its ordinary shares.
Source:Jun 4, 2026, 12:00 UTC
SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture for precision oncology.